Mazdutide Research for Type 2 Diabetes
An evidence-based overview of research examining Mazdutide in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
A phase 2 trial showed clinically meaningful glycemic control, with HbA1c reduced 1.41-1.67% vs placebo in Chinese patients with type 2 diabetes. The DREAMS-3 head-to-head trial vs semaglutide (N=349) is designed around a combined HbA1c <7% and ≥10% weight loss endpoint, with results pending. Under regulatory review in China for a T2D indication.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Mazdutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.